Show Summary Details
Page of

High-Dose Atorvastatin after Stroke or Transient Ischemic Attack: The SPARCL Trial 

High-Dose Atorvastatin after Stroke or Transient Ischemic Attack: The SPARCL Trial
Chapter:
High-Dose Atorvastatin after Stroke or Transient Ischemic Attack: The SPARCL Trial
Author(s):

Brian Mac Grory

DOI:
10.1093/med/9780199377527.003.0046
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 17 October 2019

This chapter provides a summary of a landmark study in vascular neurology. Is there evidence that a daily high dose of atorvastatin is effective for secondary stroke prevention? Starting with that question, it describes the basics of the study, including funding, study location, who was studied, how many patients, study design, study intervention, follow-up, endpoints, results, and criticism and limitations. In patients with a history of stroke or transient ischemic attack within the past 6 months, 80 mg of atorvastatin per day reduced the risk of subsequent stroke in patients without known coronary artery disease. The chapter briefly reviews other relevant studies and information, and concludes with a relevant clinical case.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.